PRAME antibody (C-Term)
Quick Overview for PRAME antibody (C-Term) (ABIN453177)
Target
See all PRAME AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Specificity
- This antibody reacts to MAPE.
-
Purification
- Saturated Ammonium Sulfate (SAS) precipitation
-
Immunogen
- KLH conjugated synthetic peptide selected from the C-terminal region of human MAPE
-
-
-
-
Application Notes
-
ELISA: 1/1,000. Western blotting: 1/50 - 1/100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
-
Alternative Name
- PRAME / MAPE
-
Background
- MAPE is an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, its gene is also expressed in acute leukemias.Synonyms: Melanoma antigen preferentially expressed in tumors, OIP-4, OIP4, OPA-interacting protein 4, Preferentially expressed antigen of melanoma
-
Gene ID
- 23532
-
NCBI Accession
- NP_006106
-
UniProt
- P78395
-
Pathways
- Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding
Target
-